论文部分内容阅读
目的探讨低分子肝素治疗过敏性紫癜(HSP)的临床疗效及其预防早期肾损害的作用。方法选择厦门市妇幼保健院儿科2011—2014年住院治疗的HSP患儿109例,应用随机数字表法分为对照组52例和观察组57例。对照组患儿予以综合治疗,观察组患儿在对照组基础上加用低分子肝素钙治疗。比较两组患儿临床疗效和尿微量清蛋白(m ALB)水平变化。结果观察组皮肤紫癜、腹痛消退时间短于对照组,皮疹反复发生率低于对照组,差异有统计学意义(P<0.05)。治疗前两组患儿m ALB水平比较,差异无统计学意义(P>0.05);治疗后观察组m ALB水平低于对照组,差异有统计学意义(P<0.05)。观察组紫癜性肾炎发生率低于对照组,差异有统计学意义(P<0.05)。结论低分子肝素钙治疗HSP,可有效缓解临床症状,有效预防早期肾损害的发生,且使用方便、不良反应少。
Objective To investigate the clinical efficacy of low molecular weight heparin in the treatment of Henoch-Schonlein purpura (HSP) and its role in preventing early renal damage. Methods 109 cases of children with HSP from 2011 to 2014 in Xiamen MCH hospital were divided into control group (n = 52) and observation group (n = 57) by random number table. The control group of children to be comprehensive treatment, observation group children in the control group based on the addition of low molecular weight heparin treatment. The clinical efficacy and urinary albumin (m ALB) levels in both groups were compared. Results The observation group skin purpura, abdominal pain subsided shorter than the control group, the recurrence rate of rash is lower than the control group, the difference was statistically significant (P <0.05). There was no significant difference in the level of m ALB between the two groups before treatment (P> 0.05). After treatment, the level of m ALB in the observation group was lower than that of the control group (P <0.05). The incidence of purpura nephritis in the observation group was lower than that in the control group, with statistical significance (P <0.05). Conclusion Low molecular weight heparin treatment of HSP, can effectively alleviate the clinical symptoms and effective prevention of early renal damage, and easy to use, less adverse reactions.